The APOE ε4/ε4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 8, 2013, Pages 1251-1258

  Hultman, Karin ^a   Strickland, Sidney ^a   Norris, Erin H ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; APOE; beta amyloid; cerebral amyloid angiopathy; fibrin(ogen); neurovasculature

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FIBRINOGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; BRAIN TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; AMYLOID PLAQUE; ATHEROSCLEROSIS; BLOOD VESSEL; BRAIN; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOLIPOPROTEIN E4; ATHEROSCLEROSIS; BLOOD VESSELS; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLAQUE, AMYLOID; SEX CHARACTERISTICS;

EID: 84881181605     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.76     Document Type: Article

References (39)

1. Bangen KJ, Delano-Wood L, Wierenga CE, McCauley A, Jeste DV, Salmon DP et al. Associations between stroke risk and cognition in normal aging and Alzheimer's disease with and without depression. Int J Geriatr Psychiatry 2010; 25: 175-182.
2. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007; 113: 13-21.
3. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 2012; 32: 425-436.
4. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
5. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-2062.
6. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611.
7. Staffen W, Bergmann J, Schonauer U, Zauner H, Kronbichler M, Golaszewski S et al. Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation. Eur J Nucl Med Mol Imaging 2009; 36: 801-810.
8. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311-324.
9. Carrano A, Hoozemans JJ, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJ. Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 2012; 10: 329-331.
10. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging 2009; 30: 1936-1948.
11. Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci 2007; 257: 49-55.
12. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 2010; 66: 695-709.
13. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
14. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005; 36: 2637-2641.
15. Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 2008; 62: 1070-1075.
16. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2009; 13: 2911-2925.
17. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci USA 2010; 107: 21812-21817.
18. Zamolodchikov D, Strickland S. A b delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 2012; 119: 3342-3351.
19. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
20. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985; 76: 1501-1513.
21. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31: 445-454.
22. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr. PC et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
23. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 2004; 23: 235-246.
24. Navarro A, Del Valle E, Astudillo A, Gonzalez del Rey C, Tolivia J. Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. Exp Neurol 2003; 184: 697-704.
25. Chalmers K, Wilcock GK, Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 2003; 29: 231-238.
26. Trembath D, Ervin JF, Broom L, Szymanski M, Welsh-Bohmer K, Pieper C et al. The distribution of cerebrovascular amyloid in Alzheimer's disease varies with ApoE genotype. Acta Neuropathol 2007; 113: 23-31.
27. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol 2010; 120: 169-183.
28. Hulette CM, Welsh-Bohmer KA, Crain B, Szymanski MH, Sinclaire NO, Roses AD. Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med 1997; 121: 615-618.
29. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 1997; 18: S91-S94.
30. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The national institute on aging, and reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997; 18: S1-S2.
31. Attems J, Jellinger KA, Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 2005; 110: 222-231.
32. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281: 4292-4299.
33. Uchikado H, Akiyama H, Kondo H, Ikeda K, Tsuchiya K, Kato M et al. Activation of vascular endothelial cells and perivascular cells by systemic inflammation-an immunohistochemical study of postmortem human brain tissues. Acta Neuropathol 2004; 107: 341-351.
34. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 2012; 32: 599-608.
35. Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 2000; 100: 395-402.
36. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997; 28: 1418-1422.
37. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995; 306(Pt 2): 599-604.
38. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758.
39. Hogh P, Knudsen GM, Kjaer KH, Jorgensen OS, Paulson OB, Waldemar G. Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon4 allele on regional cerebral blood flow. J Geriatr Psychiatry Neurol 2001; 14: 42-51.